The European experience, though, suggests a trend toward decreasing price as the biosimilars market matures. “As the market has evolved, we’ve seen discounts of 30 percent, even 75 percent,” said Dr Fuhr. Furthermore, in some cases, manufacturers of reference biologics are decreasing the cost of their drugs as well. As a result, he said, “access is increasing and costs are going down.”
Explore This Issue
August 2017He predicts that cost savings will appear here as well. “In five years, you should see considerable decreases in price.”